CA
ACAD icon

Corrado Advisors’s Acadia Pharmaceuticals ACAD Stock Holding History

Corrado Advisors’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-155
Closed -$2.47K – 118
2022
Q4 		$2.47K Buy
+155
New +$2.42K ﹤0.01% 318
2014
Q2 		– Sell
-45,075
Closed -$1.1M – 71
2014
Q1 		$1.1M Sell
45,075
-8,435
-16% -$213K 0.53% 30
2013
Q4 		$1.34M Sell
53,510
-4,825
-8% -$114K 0.6% 24
2013
Q3 		$1.6M Sell
58,335
-2,290
-4% -$47.9K 0.84% 18
2013
Q2 		$1.1M Buy
+60,625
New +$835K 0.66% 17

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Corrado Advisors's ACAD Position: Q1 2023 in Review

Corrado Advisors sold out of Acadia Pharmaceuticals (ACAD) in Q1 2023, closing a stake of 155 shares — an estimated $2.47K sold.

Corrado Advisors first reported a position in ACAD in Q2 2013 and held it in 5 quarters. The position peaked at $1.6M in Q3 2013. 233 funds tracked by Wall St. Rank hold ACAD as of Q1 2023.

  • Corrado Advisors reported no remaining Acadia Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Corrado Advisors sold 155 Acadia Pharmaceuticals shares in Q1 2023, an estimated $2.47K.
  • Corrado Advisors first reported a position in Acadia Pharmaceuticals in Q2 2013 and held it in 5 quarters.
  • Corrado Advisors's Acadia Pharmaceuticals position peaked at $1.6M in Q3 2013.
  • 233 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2023.

Based on Corrado Advisors's 13F filing for Q1 2023, filed 3 May 2023.